论文部分内容阅读
目的 研究尿激酶型纤溶酶原活因子 (uPA)及其受体 (uPAR)在神经母细胞瘤 (NB)中的表达和意义。方法 应用免疫组织化学方法研究uPA及uPAR在 42例神经母细胞瘤中的表达 ,并应用逆转录 聚合酶链式反应 (RT PCR)方法检测患儿骨髓和外周血中的神经蛋白基因产物9.5(PGP9.5)。结果 uPA及uPAR阳性表达率在进展期肿瘤 (均为 85 .7% )高于局灶期肿瘤(42 .9% ,2 8.6 % ) ;预后不良型患儿 (91 .7% ,83 .3 % )高于预后良好型患儿 (均为 44 .4 % ) ,且差异均具有非常显著性 (P <0 .0 1 )。患儿骨髓和外周血中PGP9.5阳性检出率在uPA阳性患儿组(60 .0 % )显著高于uPA阴性患儿组 (8.3 % ,P <0 .0 1 ) ;uPAR阳性组 (57.1 % )高于uPAR阴性组(2 1 .4 % ,P <0 .0 5)。uPA和uPAR同时阳性的 1 0例患儿 ,骨髓和外周血中均有PGP9.5阳性表达 ,而同时阴性的 5例患儿中 ,均未检测到PGP9.5。结论 uPA和uPAR在NB的浸润转移过程中发挥重要的作用
Objective To study the expression and significance of urokinase-type plasminogen activator (uPA) and its receptor (uPAR) in neuroblastoma (NB). Methods The expression of uPA and uPAR in 42 cases of neuroblastoma was studied by immunohistochemistry and the expression of neuropeptide gene products in bone marrow and peripheral blood was detected by reverse transcriptase-polymerase chain reaction (RT-PCR) PGP9.5). Results The positive rates of uPA and uPAR were higher in advanced stage tumors (85.7%) than those in focal stage tumors (42.9%, 22.6%). In poor prognosis children (91.7%, 83.3% %) Were higher than those with good prognosis (both 44.4%), and the difference was highly significant (P <0.01). The detection rate of PGP9.5 in bone marrow and peripheral blood of children with uPA positive group (60.0%) was significantly higher than that of uPA negative group (8.3%, P <0.01); uPAR positive group 57.1%) than in the uPAR negative group (21.4%, P <0.05). 10 cases of both uPA and uPAR positive children, PGP9.5 positive expression in bone marrow and peripheral blood, while negative 5 cases of children were not detected in PGP9.5. Conclusion uPA and uPAR play an important role in the invasion and metastasis of NB